Despite 12 Percent Drop in Q1 Sales, Meridian Bioscience Maintains Positive FY '11 Outlook
January 20, 2011
Despite 12 Percent Drop in Q1 Sales, Meridian Bioscience Maintains Positive FY '11 Outlook
Meridian maintained its guidance for fiscal year 2011 based in part on the gradual uptake of its Illumigene amplification-based C. difficile test and positive contributions from its recently acquired Bioline business.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Dx Focus: Clinical and Regulatory PCR and Nucleic Acid Testing News
March 23, 2010 / PCR Insider - Meridian Bioscience Reports 13 Percent Spike in Q1 Revenues Driven by Growth in Illumigene Products
January 24, 2013 / PCR Insider - Quidel Obtains CE Mark for AmpliVue C. Difficile, Company's First Handheld MDx Test
March 29, 2012 / PCR Insider - Meridian Bioscience's Bioline Unit to Directly Market Products in Australia
August 23, 2011 / PCR Insider - Dx Focus: Meridian Bioscience Illumigene Mycoplasma; CDC Novel Coronavirus Assay
June 13, 2013 / PCR Insider